RS63966B1 - Industrijski postupak za pripremu estetrola visoke čistoće - Google Patents
Industrijski postupak za pripremu estetrola visoke čistoćeInfo
- Publication number
- RS63966B1 RS63966B1 RS20230112A RSP20230112A RS63966B1 RS 63966 B1 RS63966 B1 RS 63966B1 RS 20230112 A RS20230112 A RS 20230112A RS P20230112 A RSP20230112 A RS P20230112A RS 63966 B1 RS63966 B1 RS 63966B1
- Authority
- RS
- Serbia
- Prior art keywords
- estetrol
- preparation
- high purity
- industrial process
- industrial
- Prior art date
Links
- AJIPIJNNOJSSQC-NYLIRDPKSA-N estetrol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)[C@@H]4O)O)[C@@H]4[C@@H]3CCC2=C1 AJIPIJNNOJSSQC-NYLIRDPKSA-N 0.000 title 1
- 229950009589 estetrol Drugs 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
- C07J1/0074—Esters
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Immunology (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1900315A HU231240B1 (hu) | 2019-09-03 | 2019-09-03 | Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására |
| EP20768398.8A EP3877395B1 (en) | 2019-09-03 | 2020-09-02 | Industrial process for the preparation of high purity estetrol |
| PCT/IB2020/058148 WO2021044302A1 (en) | 2019-09-03 | 2020-09-02 | Industrial process for the preparation of high purity estetrol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS63966B1 true RS63966B1 (sr) | 2023-03-31 |
Family
ID=89992977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20230112A RS63966B1 (sr) | 2019-09-03 | 2020-09-02 | Industrijski postupak za pripremu estetrola visoke čistoće |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US11633406B2 (sr) |
| EP (1) | EP3877395B1 (sr) |
| JP (1) | JP7265087B2 (sr) |
| KR (1) | KR20220071206A (sr) |
| CN (1) | CN114302889B (sr) |
| AU (1) | AU2020343497B2 (sr) |
| CA (1) | CA3147815C (sr) |
| CL (1) | CL2022000492A1 (sr) |
| CO (1) | CO2022003769A2 (sr) |
| CU (1) | CU24692B1 (sr) |
| DK (1) | DK3877395T3 (sr) |
| EC (1) | ECSP22022403A (sr) |
| ES (1) | ES2855923T3 (sr) |
| FI (1) | FI3877395T3 (sr) |
| GE (1) | GEP20247626B (sr) |
| HR (1) | HRP20230230T1 (sr) |
| HU (2) | HU231240B1 (sr) |
| IL (1) | IL290973B2 (sr) |
| JO (1) | JOP20220041A1 (sr) |
| LT (1) | LT3877395T (sr) |
| MA (1) | MA54200B1 (sr) |
| MD (1) | MD3877395T2 (sr) |
| MX (1) | MX2022002603A (sr) |
| PE (1) | PE20221418A1 (sr) |
| PL (1) | PL3877395T3 (sr) |
| PT (1) | PT3877395T (sr) |
| RS (1) | RS63966B1 (sr) |
| SI (1) | SI3877395T1 (sr) |
| WO (1) | WO2021044302A1 (sr) |
| ZA (1) | ZA202203557B (sr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114514237B (zh) * | 2019-09-27 | 2024-07-26 | 工业化学有限公司 | 用于制备(15α,16α,17β)-雌-1,3,5(10)-三烯-3,15,16,17-四醇(雌四醇)的工艺及所述工艺的中间体 |
| ES2976651A2 (es) * | 2021-10-01 | 2024-08-06 | Ind Chimica Srl | PROCESO PARA PREPARAR (15alfa,16alfa,17beta)-ESTRA-1,3,5(10)-TRIENO-3,15,16,17-TETROL (ESTETROL) Y ESTETROL MONOHIDRATO |
| WO2024160373A1 (en) | 2023-02-02 | 2024-08-08 | Industriale Chimica S.R.L. | PROCESS FOR PREPARING (15α,16α,17β)-ESTRA-1,3,5(10)-TRIENE-3,15,16,17-TETROL (ESTETROL) MONOHYDRATE |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002094276A1 (en) | 2001-05-18 | 2002-11-28 | Pantarhei Bioscience B.V. | Pharmaceutical composition for use in hormone replacement therapy |
| EP1260225A1 (en) | 2001-05-18 | 2002-11-27 | Pantarhei Bioscience B.V. | A pharmaceutical composition for use in hormone replacement therapy |
| EP1390041B1 (en) | 2001-05-23 | 2009-11-25 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception |
| WO2002094279A1 (en) | 2001-05-23 | 2002-11-28 | Pantarhei Bioscience B.V. | Drug delivery system comprising a tetrahidroxilated estrogen for use in hormonal contraception |
| WO2003041718A1 (en) | 2001-11-15 | 2003-05-22 | Pantarhei Bioscience B.V. | Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy |
| PT1511496E (pt) | 2002-06-11 | 2007-01-31 | Pantarhei Bioscience Bv | Método para tratamento ou prevenção de doenças mediadas pelo sistema imunitário e formulação farmacológica para utilização nas mesmas |
| US7943604B2 (en) | 2002-06-11 | 2011-05-17 | Pantarhei Bioscience B.V. | Method of treating human skin and a skin care composition for use in such a method |
| PT1526856E (pt) | 2002-07-12 | 2008-04-11 | Pantarhei Bioscience Bv | Composição farmacêutica que compreende derivados do estretol para ser utilizada no tratamento do cancro |
| CN100528167C (zh) | 2002-10-23 | 2009-08-19 | 潘塔希生物科学股份有限公司 | 用于治疗癌症的包含雌四醇衍生物的药物组合物 |
| ES2346053T3 (es) * | 2002-11-08 | 2010-10-08 | Pantarhei Bioscience B.V. | Sintesis de esterol a traves de esteroides derivados de estrona. |
| US20090221540A1 (en) | 2006-01-09 | 2009-09-03 | Pantarhei Bioscience B.V. | Method of Treating An Acute Vascular Disorder |
| CN101583363B (zh) | 2007-01-08 | 2013-08-21 | 潘塔希生物科学股份有限公司 | 治疗或预防雌性哺乳动物不育症的方法和此类方法中使用的药物试剂盒 |
| EP2383279A1 (en) | 2011-07-19 | 2011-11-02 | Pantarhei Bioscience B.V. | Process for the preparation of estetrol |
| AU2012293593B2 (en) | 2011-08-11 | 2017-03-23 | Estetra Srl | Use of estetrol as emergency contraceptive |
| WO2013050553A1 (en) | 2011-10-07 | 2013-04-11 | Estetra S.A. | Process for the production of estetrol |
| EP2653163A1 (en) | 2012-04-19 | 2013-10-23 | Université de Liège | Estrogenic components for use in the treatment of neurological disorders |
| WO2013034780A2 (en) | 2012-12-20 | 2013-03-14 | Crystal Pharma, S.A.U. | Process for the preparation of estetrol and related compounds |
| ES2624667T3 (es) * | 2013-09-18 | 2017-07-17 | Crystal Pharma, S.A.U. | Procedimiento para la preparación de estetrol |
| NZ720906A (en) | 2013-12-12 | 2022-04-29 | Estetra Sprl | Orally disintegrating solid dosage unit containing an estetrol component |
| DK3310345T3 (da) | 2015-06-18 | 2021-05-25 | Estetra Sprl | Orodispersibel tablet indeholdende estetrol |
| CR20180041A (es) | 2015-06-18 | 2018-05-03 | Mithra Pharmaceuticals S A | Unidad de dosificación orodispersable que contiene un componente estetrol. |
| LT3310346T (lt) | 2015-06-18 | 2021-06-10 | Estetra Sprl | Burnoje disperguojama tabletė, turinti estetrolio |
| CA3178291A1 (en) | 2016-08-05 | 2018-04-12 | Estetra Srl | Method for the management of dysmenorrhea and menstrual pain |
| JP2018533542A (ja) | 2016-10-28 | 2018-11-15 | エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ | 月経困難症および月経痛の管理のための方法 |
| PL3661520T3 (pl) | 2017-08-01 | 2022-03-28 | Fund Sa | Terapia adiuwantowa do stosowania w leczeniu raka prostaty |
| JP2021513507A (ja) | 2018-02-07 | 2021-05-27 | エステトラ ソシエテ プリーヴ ア レスポンサビリテ リミテ | 心臓血管系への影響を低減した避妊薬組成物 |
| CN114514237B (zh) | 2019-09-27 | 2024-07-26 | 工业化学有限公司 | 用于制备(15α,16α,17β)-雌-1,3,5(10)-三烯-3,15,16,17-四醇(雌四醇)的工艺及所述工艺的中间体 |
-
2019
- 2019-09-03 HU HU1900315A patent/HU231240B1/hu unknown
-
2020
- 2020-09-02 AU AU2020343497A patent/AU2020343497B2/en active Active
- 2020-09-02 LT LTEPPCT/IB2020/058148T patent/LT3877395T/lt unknown
- 2020-09-02 WO PCT/IB2020/058148 patent/WO2021044302A1/en active Application Filing
- 2020-09-02 US US17/639,206 patent/US11633406B2/en active Active
- 2020-09-02 MD MDE20210894T patent/MD3877395T2/ro unknown
- 2020-09-02 JO JOP/2022/0041A patent/JOP20220041A1/ar unknown
- 2020-09-02 EP EP20768398.8A patent/EP3877395B1/en active Active
- 2020-09-02 PT PT207683988T patent/PT3877395T/pt unknown
- 2020-09-02 SI SI202030156T patent/SI3877395T1/sl unknown
- 2020-09-02 IL IL290973A patent/IL290973B2/en unknown
- 2020-09-02 ES ES20768398T patent/ES2855923T3/es active Active
- 2020-09-02 PL PL20768398.8T patent/PL3877395T3/pl unknown
- 2020-09-02 GE GEAP202015920A patent/GEP20247626B/en unknown
- 2020-09-02 CA CA3147815A patent/CA3147815C/en active Active
- 2020-09-02 MA MA54200A patent/MA54200B1/fr unknown
- 2020-09-02 RS RS20230112A patent/RS63966B1/sr unknown
- 2020-09-02 CN CN202080061521.1A patent/CN114302889B/zh active Active
- 2020-09-02 FI FIEP20768398.8T patent/FI3877395T3/fi active
- 2020-09-02 HR HRP20230230TT patent/HRP20230230T1/hr unknown
- 2020-09-02 PE PE2022000348A patent/PE20221418A1/es unknown
- 2020-09-02 DK DK20768398.8T patent/DK3877395T3/da active
- 2020-09-02 JP JP2022511285A patent/JP7265087B2/ja active Active
- 2020-09-02 MX MX2022002603A patent/MX2022002603A/es unknown
- 2020-09-02 KR KR1020227010919A patent/KR20220071206A/ko unknown
- 2020-09-02 HU HUE20768398A patent/HUE061427T2/hu unknown
- 2020-09-02 CU CU2022000013A patent/CU24692B1/es unknown
-
2022
- 2022-02-28 CL CL2022000492A patent/CL2022000492A1/es unknown
- 2022-03-24 EC ECSENADI202222403A patent/ECSP22022403A/es unknown
- 2022-03-28 ZA ZA2022/03557A patent/ZA202203557B/en unknown
- 2022-03-29 CO CONC2022/0003769A patent/CO2022003769A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276917A (en) | A process for the preparation of alubixivet | |
| ZA202203557B (en) | Industrial process for the preparation of high purity estetrol | |
| GB2593352B (en) | Process for the preparation of 3alpha-hydroxy-5alpha-pregnan-20-one (brexanolone) | |
| SG11202005382YA (en) | Process for the preparation of microcapsules | |
| EP3694499A4 (en) | NEW LIFITEGRAST PREPARATION PROCESS | |
| SG11202108238VA (en) | Process for the preparation of methionine | |
| LT3765440T (lt) | N-alkil-nitratoetilnitraminų gamybos būdas | |
| IL289904A (en) | A process for preparing biphenylamines | |
| IL290181A (en) | Process for the preparation of Fluensulfone | |
| IL289453A (en) | A process for the preparation of ridinilazole and crystalline forms thereof | |
| IL281254A (en) | A process for the preparation of lanbatinib | |
| PT3947393T (pt) | Processo para a preparação de midostaurina com elevada pureza | |
| EP3877361C0 (en) | PROCESS FOR PREPARING ARYLSULFONYLPROPENENITRILE | |
| EP3727377A4 (en) | PROCESS FOR THE PREPARATION OF PYRIMIDINYL-4-AMINOPYRAZOLE COMPOUNDS | |
| SG11202101575TA (en) | Process for the production of high purity isobutylene | |
| IL286054A (en) | A process for the preparation of a modified imidazoquinoline | |
| IL285550A (en) | Process for preparing polyamides | |
| IL279410A (en) | Process for preparing Quinmark | |
| EP4077278A4 (en) | METHOD FOR PRODUCING BRIVARACETAM | |
| PL3599256T3 (pl) | Sposób wytwarzania poliorganosiloksanów | |
| HUP2300098A1 (hu) | Eljárás upadacitinib elõállítására | |
| IL290215A (en) | A process for the preparation of crystalline form ii of sotagliflozin | |
| PL3458522T3 (pl) | Proces otrzymywania związków diaminofenotiazynowych o wysokim stopniu czystości | |
| HUP1800278A2 (en) | Process for the preparation of boc-linagliptin | |
| IL274560A (en) | A process for the preparation of raltagravir |